Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis.1 Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya),2 are also approved for treatment of CD.